3 Growth Companies With High Insider Ownership Growing Revenues At 43%

In This Article:

In the current landscape, global markets have shown mixed performances, with major U.S. stock indexes like the S&P 500 and Nasdaq Composite reaching record highs amid a rally in growth stocks, while geopolitical events and economic reports continue to influence investor sentiment. Amidst this backdrop of fluctuating indices and sector-specific gains, identifying growth companies with high insider ownership can be compelling for investors seeking alignment of interests between company insiders and shareholders.

Top 10 Growth Companies With High Insider Ownership

Name

Insider Ownership

Earnings Growth

People & Technology (KOSDAQ:A137400)

16.4%

37.3%

Kirloskar Pneumatic (BSE:505283)

30.3%

26.3%

Archean Chemical Industries (NSEI:ACI)

22.9%

41.3%

Laopu Gold (SEHK:6181)

36.4%

34.2%

Medley (TSE:4480)

34%

31.7%

Plenti Group (ASX:PLT)

12.8%

120.1%

Fine M-TecLTD (KOSDAQ:A441270)

17.2%

131.1%

Fulin Precision (SZSE:300432)

13.6%

66.7%

HANA Micron (KOSDAQ:A067310)

18.4%

110.9%

Findi (ASX:FND)

34.8%

112.9%

Click here to see the full list of 1510 stocks from our Fast Growing Companies With High Insider Ownership screener.

Let's review some notable picks from our screened stocks.

Angelalign Technology

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Angelalign Technology Inc. is an investment holding company that focuses on researching, developing, designing, manufacturing, and marketing clear aligner treatment solutions in the People's Republic of China with a market cap of HK$10.02 billion.

Operations: The company's revenue primarily comes from its Dental Equipment & Supplies segment, which generated CN¥1.72 billion.

Insider Ownership: 18.4%

Revenue Growth Forecast: 15.3% p.a.

Angelalign Technology is poised for robust growth, with earnings projected to increase by 67.04% annually, outpacing the Hong Kong market. Despite a decline in profit margins from 13.1% to 2.5%, the company trades slightly below its fair value estimate and analysts anticipate a 36.2% price rise. However, Return on Equity is expected to remain low at 6.5%. Revenue growth of 15.3% annually also surpasses market averages but remains under the high-growth threshold.

SEHK:6699 Earnings and Revenue Growth as at Dec 2024
SEHK:6699 Earnings and Revenue Growth as at Dec 2024

BrightGene Bio-Medical Technology

Simply Wall St Growth Rating: ★★★★★☆

Overview: BrightGene Bio-Medical Technology Co., Ltd. is a pharmaceutical company involved in the research, development, manufacture, and commercialization of pharmaceutical products in China, with a market cap of CN¥13.24 billion.